Cargando…
The pyrazolyl-urea GeGe3 inhibits tumor angiogenesis and reveals dystrophia myotonica protein kinase (DMPK)1 as a novel angiogenesis target
The limitation of targeting VEGF/VEGFR2 signalling to stop angiogenesis in cancer therapy has been blamed on re-activation of alternative receptor tyrosine kinases by compensatory angiogenic factors. Targeting MAPK and PI3K signaling pathways in endothelial cells may be an alternative or complementa...
Autores principales: | Meta, Elda, Imhof, Beat A., Ropraz, Patricia, Fish, Richard J., Brullo, Chiara, Bruno, Olga, Sidibé, Adama |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5746136/ https://www.ncbi.nlm.nih.gov/pubmed/29296234 http://dx.doi.org/10.18632/oncotarget.22598 |
Ejemplares similares
-
The Pyrazolyl-Urea Gege3 Inhibits the Activity of ANXA1 in the Angiogenesis Induced by the Pancreatic Cancer Derived EVs
por: Belvedere, Raffaella, et al.
Publicado: (2021) -
Dystrophia Myotonica: A Family History
por: Parker, William A.
Publicado: (1948) -
DDX6 regulates sequestered nuclear CUG-expanded DMPK-mRNA in dystrophia myotonica type 1
por: Pettersson, Olof J., et al.
Publicado: (2014) -
“Dystrophia Myotonica” and the Legacy of Hans Gustav Wilhelm Steinert
por: Mishra, Shri Kant, et al.
Publicado: (2018) -
Biological evaluation of pyrazolyl-urea and dihydro-imidazo-pyrazolyl-urea derivatives as potential anti-angiogenetic agents in the treatment of neuroblastoma
por: Marengo, Barbara, et al.
Publicado: (2020)